A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. (AML18 Pilot)
This study is currently recruiting participants.
Verified April 2013 by Cardiff University
Sponsor:
Cardiff University
Collaborators:
Leukaemia & Lymphoma Research Group
Experimental Cancer Medicine Centre Network
Information provided by (Responsible Party):
Alan K Burnett, Cardiff University
ClinicalTrials.gov Identifier:
NCT01236144
First received: November 5, 2010
Last updated: April 25, 2013
Last verified: April 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | August 2014 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |